LASP1 and chronic myelogenous leukemia, BCR-ABL1 positive: The present work now demonstrates that low LASP1 levels, as observed in TKI non‐responders and blast crisis patients, affect proliferation, migration and cytokine release in the CML cell line K562 and might contribute to worse patient outcome.